<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of iron deficiency in chronic kidney disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of iron deficiency in chronic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of iron deficiency in chronic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anemia is common among patients with chronic kidney disease (CKD), including those on dialysis. Anemia underlies many of the symptoms associated with reduced kidney function and is associated with increased mortality and hospitalizations [<a href="#rid1">1-4</a>]. Iron deficiency is the most common reversible cause of anemia among such patients.</p><p>This topic reviews methods to diagnose iron deficiency in individuals with CKD. The treatment of iron deficiency in nondialysis CKD, peritoneal dialysis, and hemodialysis patients is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1943.html" rel="external">"Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)"</a> and  <a class="medical medical_review" href="/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis"</a>.)</p><p>Overall approaches to anemia in nondialysis CKD, peritoneal dialysis, and hemodialysis patients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H2972691509"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Patients may have either absolute or functional iron deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absolute iron deficiency</strong> – Absolute iron deficiency is defined by severely reduced or absent storage iron in bone marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional iron deficiency</strong> – Functional (or relative) iron deficiency is characterized by adequate iron stores (defined by stainable iron in bone marrow) but insufficient iron availability for incorporation into erythroid precursors [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1">Functional iron deficiency is related in part to the administration of erythropoiesis-stimulating agents (ESAs). Among such patients, total body iron stores are adequate, but iron release from these stores into the circulation is not rapid enough to provide sufficient iron to support the increased erythropoietic rate being driven by the ESA.</p><p></p><p class="bulletIndent1">However, many CKD patients also have anemia of chronic disease, which is related to an underlying inflammatory state [<a href="#rid7">7</a>]. Anemia of chronic disease is mediated in part by upregulation of hepcidin by inflammatory cytokines [<a href="#rid8">8,9</a>]. Hepcidin is a hormone that is produced and secreted by the liver and inhibits release of iron from reticuloendothelial macrophages and hepatocytes into plasma [<a href="#rid6">6</a>]. Hepcidin levels are increased in CKD patients [<a href="#rid10">10-13</a>].</p><p></p><p class="bulletIndent1">It is clinically important to determine whether functional iron deficiency is related to ESA therapy or to anemia of chronic disease with an "inflammatory blockade" of available iron. However, it is often difficult to distinguish between these possibilities. The distinction is often made retrospectively after observing the erythropoietic response to administration of intravenous iron with or without a concomitant increase in ESA dose.</p><p></p><p class="bulletIndent1">Functional iron deficiency related to ESA administration may respond to intravenous iron, while anemia of chronic disease is probably less likely to improve. The response to intravenous iron and an increase in ESA dose among patients thought to have functional iron deficiency was examined in the Dialysis Patients' Response to Intravenous Iron with Elevated Ferritin (DRIVE) study in which 134 patients with anemia, elevated ferritin levels (500 to 1200 ng/mL), low transferrin saturation (TSAT) levels (≤25 percent), and high ESA requirements were randomly assigned to <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> or placebo along with a 25 percent increase in ESA dose [<a href="#rid14">14</a>]. At six weeks, hemoglobin (Hb) levels had increased significantly more in the active-therapy group (1.6 versus 1.1 g/dL) [<a href="#rid15">15</a>]. Clinical outcomes beyond an increase in Hb level were not assessed, and the long-term safety of this approach is not established.</p><p></p><p>Diagnostic tests for absolute and functional iron deficiency are discussed below.</p><p class="headingAnchor" id="H45263676"><span class="h1">COMMONLY USED TESTS</span><span class="headingEndMark"> — </span>Ideally, diagnostic tests for anemia should detect iron deficiency (both absolute and functional) and predict whether patients will respond to administered iron. There is no single test that does both.</p><p>The gold standard for the diagnosis of iron deficiency is measurement of iron stores in bone marrow obtained on biopsy (see  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'</a>). However, bone marrow biopsies to assess iron stores are rarely done in CKD patients. Instead, iron stores are more commonly estimated by:</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of serum iron, total iron-binding capacity (TIBC), and ferritin and calculation of the percent transferrin saturation (TSAT)</p><p></p><p class="bulletIndent1">or by</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determination of the percentage of hypochromic red blood cells (HRCs) and determination of the reticulocyte hemoglobin (Hb) content (CHr)</p><p></p><p>In the United States, measurement of the serum iron, TIBC, and ferritin and TSAT is more commonly used. The percentage of HRC and Hb content tests may be more extensively used in Europe but are not widely available or used in the United States. (See <a class="local">'Percent hypochromic HRCs and reticulocyte hemoglobin content'</a> below.)</p><p>Both approaches are discussed below.</p><p class="headingAnchor" id="H1179625300"><span class="h2">Serum iron, total iron-binding capacity, ferritin, and transferrin saturation</span><span class="headingEndMark"> — </span>Measurement of these parameters is commonly used to identify iron deficiency. Laboratory criteria used to define iron deficiency and provide indication for treatment are markedly different among CKD patients compared with patients with normal kidney function. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnosis'</a>.)</p><p>The TSAT and ferritin criteria are different for absolute and functional iron deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absolute iron deficiency </strong>– Among CKD patients, absolute iron deficiency, defined by diminished or absent bone marrow iron stores on biopsy, is likely to be present in patients when [<a href="#rid16">16-19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The percent TSAT (plasma iron divided by TIBC x 100) is ≤20 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The serum ferritin concentration is ≤100 ng/mL among patients with nondialysis CKD or those receiving peritoneal dialysis, or is ≤200 ng/mL among patients receiving hemodialysis. This difference in the serum ferritin level is based upon evidence in hemodialysis patients that the maintenance of ferritin levels &gt;200 ng/mL is associated with decreased erythropoietin requirements.</p><p></p><p class="bulletIndent1">By comparison, patients with normal kidney function and severe iron deficiency anemia typically have a serum ferritin concentration &lt;30 ng/mL. The ferritin is commonly higher among iron-deficient CKD patients because it increases in response to diffuse inflammation, which characterizes advanced renal failure and dialysis [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>.)</p><p></p><p class="bulletIndent1">When the ferritin is above 100 to 200 ng/mL, most patients will have stainable bone marrow iron that would be considered sufficient among patients without CKD.</p><p></p><p class="bulletIndent1">However, among hemodialysis patients, neither the TSAT nor serum ferritin accurately predicts which patients will have an improved response to ESAs after iron supplementation [<a href="#rid22">22</a>]. Many hemodialysis patients with TSAT 20 to 30 percent and serum ferritin 200 to 500 ng/mL will respond to supplemental iron administration with an increase in Hb level and/or reduction in ESA dose [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1">As a result, such patients are commonly treated with iron prior to treatment with an ESA. Despite the fact that patients with TSAT &gt;30 percent and ferritin &gt;500 ng/mL are unlikely to respond to iron supplementation, intravenous iron supplementation for such patients is common in the United States. Some clinicians continue to administer intravenous iron supplementation even among patients with a serum ferritin &gt;800 ng/dL. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional iron deficiency </strong>– As noted above, in addition to absolute iron deficiency, hemodialysis patients may also have functional iron deficiency related to ESA administration or to anemia of chronic disease. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1">Both ESA-induced functional deficiency and anemia of chronic disease are characterized by TSAT that is commonly ≤20 percent and elevated ferritin levels (as high as 800 ng/mL or even higher). Patients with ESA-induced functional iron deficiency may respond to intravenous iron in association with a concomitant increase in ESA dose with a decrease in ferritin levels.</p><p></p><p class="bulletIndent1">By contrast, anemia of chronic disease is most likely present if the weekly administration of intravenous iron (50 to 125 mg) for up to 8 to 10 doses fails to result in increased erythropoiesis; instead, this course of iron therapy typically results in a progressive increase in ferritin concentration.</p><p></p><p class="bulletIndent1">Oral iron administration is of little or no value in distinguishing absolute or functional iron deficiency from inflammatory states since iron absorption is low in all of these conditions and oral iron is generally ineffective in treating anemia in dialysis patients. (See  <a class="medical medical_review" href="/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis", section on 'Dosing and administration'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Percent hypochromic HRCs and reticulocyte hemoglobin content</span><span class="headingEndMark"> — </span>The percent hypochromic red blood cells (HRCs) and the CHr estimate the Hb content of red blood cells, not the amount of stored iron. As a result, they are more sensitive indicators of functional iron deficiency and are as good as or possibly better than the serum iron, TSAT, and ferritin at predicting whether or not a patient will respond to iron administration. A meta-analysis performed for the 2016 National Institute for Health and Care Excellence (NICE) guidelines demonstrated that HRC &gt;6 percent predicted patients who would respond to iron as well as a TSAT &lt;20 percent and ferritin &lt;100 ng/mL [<a href="#rid23">23</a>]. The negative predictive value was better with percent HRC compared with TSAT and ferritin. However, the studies comprising the meta-analysis are limited, and comparisons with TSAT &lt;20 percent and ferritin &gt;100 ng/mL are lacking.</p><p>Both percent HRC and CHr can be assessed by flow cytometry, although not all laboratories have the capacity to perform the analysis [<a href="#rid24">24-28</a>].</p><p>The following thresholds are used to diagnose iron deficiency [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Percent HRC &gt;6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>CHr &lt;29 pg</p><p></p><p>The NICE guidelines thus recommend that iron deficiency be diagnosed using HRC or CHr.</p><p class="bulletIndent1"><span class="glyph">●</span>In order for the percent HRC to be accurately measured, blood samples must be processed within six hours to prevent red cell swelling. Most outpatient dialysis facilities in the United States do not use this test for this reason. NICE guidelines recommend use of CHr if testing within six hours is not possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neither the percent HRC nor the CHr can be used in individuals with hemoglobinopathies such as thalassemia or thalassemia trait, which are characterized by decreased Hb production [<a href="#rid23">23</a>]. The NICE guidelines recommend use of TSAT and ferritin in such patients (but not either alone).</p><p></p><p>In addition, neither the percent HRC nor the CHr distinguishes functional from absolute iron deficiency.</p><p class="headingAnchor" id="H2019968224"><span class="h2">Other</span><span class="headingEndMark"> — </span>Measurement of serum hepcidin levels has also been examined for utility in assessing possible responsiveness to supplemental iron but remains experimental at this time [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H2411731727"><span class="h1">DIAGNOSIS AND INDICATIONS FOR TREATMENT</span><span class="headingEndMark"> — </span>The thresholds for treating CKD patients with iron vary according to patient group and are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>For nondialysis CKD patients (see  <a class="medical medical_review" href="/d/html/1943.html" rel="external">"Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)", section on 'Indications for treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on hemodialysis (see  <a class="medical medical_review" href="/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis", section on 'Indications'</a>)</p><p></p><p class="headingAnchor" id="H2124883062"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111938.html" rel="external">"Society guideline links: Anemia in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia is common among patients with chronic kidney disease (CKD), including those on dialysis. Iron deficiency is the most common reversible cause of anemia among such patients. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients may have either absolute or functional iron deficiency. Absolute iron deficiency is defined by severely reduced or absent storage iron in bone marrow, liver, and spleen. Functional iron deficiency is characterized by adequate iron stores (defined by stainable iron in bone marrow) but insufficient incorporation into erythroid precursors. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among CKD patients, particularly those on dialysis, functional iron deficiency is related in part to the administration of erythropoiesis-stimulating agents (ESAs; which causes an erythropoietic rate that exceeds the release of iron from stores into circulation) and to the anemia of chronic disease. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among CKD patients, commonly used methods for the diagnosis of iron deficiency include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of serum iron, total iron-binding capacity (TIBC), and ferritin and calculation of the percent transferrin saturation (TSAT).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Determination of the percentage of hypochromic red blood cells (HRCs) and determination of the reticulocyte hemoglobin content (CHr).</p><p></p><p class="bulletIndent1">While measurement of iron stores in bone marrow obtained on biopsy is considered the gold standard for the diagnosis of iron deficiency, bone marrow biopsies are rarely performed among CKD patients. (See <a class="local">'Commonly used tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, measurement of the serum iron, TIBC, and ferritin and TSAT is more commonly used although they are not highly accurate for determining total body iron stores or response to iron supplementation. The HRC and CHr may be more extensively used in Europe but are not widely available in the United States. (See <a class="local">'Commonly used tests'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610.</a></li><li><a class="nounderline abstract_t">Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309.</a></li><li><a class="nounderline abstract_t">Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465.</a></li><li><a class="nounderline abstract_t">Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20:345.</a></li><li><a class="nounderline abstract_t">Thomas DW, Hinchliffe RF, Briggs C, et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013; 161:639.</a></li><li><a class="nounderline abstract_t">Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23:1631.</a></li><li><a class="nounderline abstract_t">Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3:1691.</a></li><li><a class="nounderline abstract_t">Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271.</a></li><li><a class="nounderline abstract_t">Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41:482.</a></li><li><a class="nounderline abstract_t">Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55:726.</a></li><li><a class="nounderline abstract_t">Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008; 112:4292.</a></li><li><a class="nounderline abstract_t">Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75:976.</a></li><li><a class="nounderline abstract_t">Zaritsky J, Young B, Wang HJ, et al. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1051.</a></li><li><a class="nounderline abstract_t">Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975.</a></li><li><a class="nounderline abstract_t">Singh AK, Coyne DW, Shapiro W, et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71:1163.</a></li><li><a class="nounderline abstract_t">Fernández-Rodríguez AM, Guindeo-Casasús MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999; 34:508.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Höffken B, Wünsch H, et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26:292.</a></li><li><a class="nounderline abstract_t">Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 55:639.</a></li><li><a class="nounderline abstract_t">Stancu S, Bârsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010; 5:409.</a></li><li><a class="nounderline abstract_t">Nissenson AR. Achieving target hematocrit in dialysis patients: new concepts in iron management. Am J Kidney Dis 1997; 30:907.</a></li><li><a class="nounderline abstract_t">Rocha LA, Barreto DV, Barreto FC, et al. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:105.</a></li><li><a class="nounderline abstract_t">Babitt JL, Eisenga MF, Haase VH, et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2021; 99:1280.</a></li><li><a class="nounderline abstract_t">Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale. Am J Kidney Dis 2016; 67:548.</a></li><li><a class="nounderline abstract_t">Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 1998; 13:847.</a></li><li><a class="nounderline abstract_t">Sunder-Plassmann G, Hörl WH. Laboratory diagnosis of anaemia in dialysis patients: use of common laboratory tests. Curr Opin Nephrol Hypertens 1997; 6:566.</a></li><li><a class="nounderline abstract_t">Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30:912.</a></li><li><a class="nounderline abstract_t">Bovy C, Tsobo C, Crapanzano L, et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999; 56:1113.</a></li><li><a class="nounderline abstract_t">Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60:2406.</a></li><li><a class="nounderline abstract_t">Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25:3996.</a></li><li><a class="nounderline abstract_t">Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:1681.</a></li></ol></div><div id="topicVersionRevision">Topic 1951 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073612" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hematocrit level and associated mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10361870" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hematocrit levels and hospitalization risks in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675424" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928336" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of hematocrit on morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23573815" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guideline for the laboratory diagnosis of functional iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935483" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mechanisms of anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922994" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15124018" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252486" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20189278" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689548" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immunoassay for human serum hepcidin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19212416" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406957" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267740" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17396118" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469862" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnosis of iron deficiency in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645533" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20079959" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019121" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398140" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Achieving target hematocrit in dialysis patients: new concepts in iron management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842949" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33839163" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763385" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9568837" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9375271" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Laboratory diagnosis of anaemia in dialysis patients: use of common laboratory tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398141" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469381" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Factors determining the percentage of hypochromic red blood cells in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737617" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized trial of iron deficiency testing strategies in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20538788" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20724518" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Current status of the measurement of blood hepcidin levels in chronic kidney disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
